- Home
- ANIP vs IRON Comparison
ANIP vs IRON Comparison
Compare ANIP & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANIP
- IRON
- Stock Information
- Founded
- ANIP 2001
- IRON 2017
- Country
- ANIP United States
- IRON United States
- Employees
- ANIP N/A
- IRON N/A
- Industry
- ANIP Biotechnology: Pharmaceutical Preparations
- IRON Biotechnology: Pharmaceutical Preparations
- Sector
- ANIP Health Care
- IRON Health Care
- Exchange
- ANIP Nasdaq
- IRON Nasdaq
- Market Cap
- ANIP 1.5B
- IRON 1.4B
- IPO Year
- ANIP N/A
- IRON N/A
- Fundamental
- Price
- ANIP $59.99
- IRON $48.09
- Analyst Decision
- ANIP Strong Buy
- IRON Strong Buy
- Analyst Count
- ANIP 8
- IRON 9
- Target Price
- ANIP $80.13
- IRON $93.89
- AVG Volume (30 Days)
- ANIP 472.7K
- IRON 366.5K
- Earning Date
- ANIP 05-09-2025
- IRON 05-07-2025
- Dividend Yield
- ANIP N/A
- IRON N/A
- EPS Growth
- ANIP N/A
- IRON N/A
- EPS
- ANIP N/A
- IRON N/A
- Revenue
- ANIP $674,068,000.00
- IRON N/A
- Revenue This Year
- ANIP $27.77
- IRON N/A
- Revenue Next Year
- ANIP $7.88
- IRON N/A
- P/E Ratio
- ANIP N/A
- IRON N/A
- Revenue Growth
- ANIP 30.27
- IRON N/A
- 52 Week Low
- ANIP $52.50
- IRON $28.25
- 52 Week High
- ANIP $73.72
- IRON $68.73
- Technical
- Relative Strength Index (RSI)
- ANIP 31.13
- IRON 55.80
- Support Level
- ANIP $68.50
- IRON $44.80
- Resistance Level
- ANIP $62.60
- IRON $47.45
- Average True Range (ATR)
- ANIP 3.13
- IRON 3.00
- MACD
- ANIP -1.50
- IRON 0.34
- Stochastic Oscillator
- ANIP 5.55
- IRON 75.05
About ANIP ANI Pharmaceuticals Inc.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.